Review



rabbit polyclonal antibody directed against cd206  (Clinisciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Clinisciences rabbit polyclonal antibody directed against cd206
    GRP94 and <t>CD206</t> are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).
    Rabbit Polyclonal Antibody Directed Against Cd206, supplied by Clinisciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal antibody directed against cd206/product/Clinisciences
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal antibody directed against cd206 - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT"

    Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

    Journal: Cells

    doi: 10.3390/cells10123393

    GRP94 and CD206 are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).
    Figure Legend Snippet: GRP94 and CD206 are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).

    Techniques Used: Immunostaining

    SPECT/CT imaging with 99m Tc-Tilmanocept can specifically detect CD206 + cells in vivo. ( A ) Representative SPECT/CT images of 4T1 tumor-bearing mice at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20× excess of cold Tilmanocept (4T1 blocking, n = 6). Results are presented as the median with the interquartile range. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups (* p = 0.0293). ( B ) The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice at 24 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20x excess of cold Tilmanocept (4T1 blocking, n = 6) measured by gamma counting (*** p = 0.0007).
    Figure Legend Snippet: SPECT/CT imaging with 99m Tc-Tilmanocept can specifically detect CD206 + cells in vivo. ( A ) Representative SPECT/CT images of 4T1 tumor-bearing mice at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20× excess of cold Tilmanocept (4T1 blocking, n = 6). Results are presented as the median with the interquartile range. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups (* p = 0.0293). ( B ) The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice at 24 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20x excess of cold Tilmanocept (4T1 blocking, n = 6) measured by gamma counting (*** p = 0.0007).

    Techniques Used: Single Photon Emission Computed Tomography, Imaging, In Vivo, Injection, Blocking Assay

    GRP94 inhibition by PU-WS13 induces a decrease in 99m Tc-Tilmanocept tumor uptake in vivo. ( A ). Representative SPECT/CT images of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept. Tumors are highlighted with circles. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups. Results are presented as the median with the interquartile range, ** p = 0.0011. ( B ). The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept measured by gamma counting. Results are presented as the median with the interquartile range. * p = 0.0328. ( C ). Representative images (vehicle n = 9, PU-WS13 n = 9) and quantification of CD206 staining in 4T1 tumors from mice treated or not with PU-WS13 from D11 up to D22. Results are presented as the median with the interquartile range. ** p = 0.0056.
    Figure Legend Snippet: GRP94 inhibition by PU-WS13 induces a decrease in 99m Tc-Tilmanocept tumor uptake in vivo. ( A ). Representative SPECT/CT images of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept. Tumors are highlighted with circles. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups. Results are presented as the median with the interquartile range, ** p = 0.0011. ( B ). The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept measured by gamma counting. Results are presented as the median with the interquartile range. * p = 0.0328. ( C ). Representative images (vehicle n = 9, PU-WS13 n = 9) and quantification of CD206 staining in 4T1 tumors from mice treated or not with PU-WS13 from D11 up to D22. Results are presented as the median with the interquartile range. ** p = 0.0056.

    Techniques Used: Inhibition, In Vivo, Single Photon Emission Computed Tomography, Injection, Staining



    Similar Products

    rabbit polyclonal antibody directed against cd206  (Clinisciences)
    90
    Clinisciences rabbit polyclonal antibody directed against cd206
    GRP94 and <t>CD206</t> are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).
    Rabbit Polyclonal Antibody Directed Against Cd206, supplied by Clinisciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal antibody directed against cd206/product/Clinisciences
    Average 90 stars, based on 1 article reviews
    rabbit polyclonal antibody directed against cd206 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    GRP94 and CD206 are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).

    Journal: Cells

    Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

    doi: 10.3390/cells10123393

    Figure Lengend Snippet: GRP94 and CD206 are co-expressed in murine and some human TNBC tumors. ( A ). Representative immunostaining of GRP94 (red) and CD206 (green) in 4T1 tumor-bearing mice ( n = 8). ( B ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor infiltrated with CD206 + M2-like macrophages ( n = 3). ( C ). Representative immunostaining of GRP94 (red) and CD206 (green) in a biopsy from a human TNBC tumor non infiltrated with CD206 + M2-like macrophages ( n = 3).

    Article Snippet: The tissues were then stained with a rabbit polyclonal antibody directed against CD206 (1/100; LS-B9805-200, Clinisciences, Nanterre, France), GRP94 antibody (1/100; LS B3418, Clinisciences, Nanterre, France), or against CD8 (1/200; NBP2-29475, Novusbio, Noyal Châtillon sur Seiche, France) overnight at 4 °C.

    Techniques: Immunostaining

    SPECT/CT imaging with 99m Tc-Tilmanocept can specifically detect CD206 + cells in vivo. ( A ) Representative SPECT/CT images of 4T1 tumor-bearing mice at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20× excess of cold Tilmanocept (4T1 blocking, n = 6). Results are presented as the median with the interquartile range. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups (* p = 0.0293). ( B ) The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice at 24 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20x excess of cold Tilmanocept (4T1 blocking, n = 6) measured by gamma counting (*** p = 0.0007).

    Journal: Cells

    Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

    doi: 10.3390/cells10123393

    Figure Lengend Snippet: SPECT/CT imaging with 99m Tc-Tilmanocept can specifically detect CD206 + cells in vivo. ( A ) Representative SPECT/CT images of 4T1 tumor-bearing mice at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20× excess of cold Tilmanocept (4T1 blocking, n = 6). Results are presented as the median with the interquartile range. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups (* p = 0.0293). ( B ) The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice at 24 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept (4T1, n = 8) or 15 MBq/100 µL of 99m Tc-Tilmanocept with a 20x excess of cold Tilmanocept (4T1 blocking, n = 6) measured by gamma counting (*** p = 0.0007).

    Article Snippet: The tissues were then stained with a rabbit polyclonal antibody directed against CD206 (1/100; LS-B9805-200, Clinisciences, Nanterre, France), GRP94 antibody (1/100; LS B3418, Clinisciences, Nanterre, France), or against CD8 (1/200; NBP2-29475, Novusbio, Noyal Châtillon sur Seiche, France) overnight at 4 °C.

    Techniques: Single Photon Emission Computed Tomography, Imaging, In Vivo, Injection, Blocking Assay

    GRP94 inhibition by PU-WS13 induces a decrease in 99m Tc-Tilmanocept tumor uptake in vivo. ( A ). Representative SPECT/CT images of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept. Tumors are highlighted with circles. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups. Results are presented as the median with the interquartile range, ** p = 0.0011. ( B ). The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept measured by gamma counting. Results are presented as the median with the interquartile range. * p = 0.0328. ( C ). Representative images (vehicle n = 9, PU-WS13 n = 9) and quantification of CD206 staining in 4T1 tumors from mice treated or not with PU-WS13 from D11 up to D22. Results are presented as the median with the interquartile range. ** p = 0.0056.

    Journal: Cells

    Article Title: The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99m Tc-Tilmanocept SPECT

    doi: 10.3390/cells10123393

    Figure Lengend Snippet: GRP94 inhibition by PU-WS13 induces a decrease in 99m Tc-Tilmanocept tumor uptake in vivo. ( A ). Representative SPECT/CT images of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept. Tumors are highlighted with circles. The scatter dot plot represents the percentage of the injected dose of 99m Tc-Tilmanocept per gram of tumor (%ID/g) for both groups. Results are presented as the median with the interquartile range, ** p = 0.0011. ( B ). The scatter dot plot represents the percentage of injected dose of 99m Tc-Tilmanocept per gram of tumor of 4T1 tumor-bearing mice receiving vehicle ( n = 8) or PU-WS13 ( n = 9) from D11 up to D22 at 1 h post-injection of 15 MBq/100 µL of 99m Tc-Tilmanocept measured by gamma counting. Results are presented as the median with the interquartile range. * p = 0.0328. ( C ). Representative images (vehicle n = 9, PU-WS13 n = 9) and quantification of CD206 staining in 4T1 tumors from mice treated or not with PU-WS13 from D11 up to D22. Results are presented as the median with the interquartile range. ** p = 0.0056.

    Article Snippet: The tissues were then stained with a rabbit polyclonal antibody directed against CD206 (1/100; LS-B9805-200, Clinisciences, Nanterre, France), GRP94 antibody (1/100; LS B3418, Clinisciences, Nanterre, France), or against CD8 (1/200; NBP2-29475, Novusbio, Noyal Châtillon sur Seiche, France) overnight at 4 °C.

    Techniques: Inhibition, In Vivo, Single Photon Emission Computed Tomography, Injection, Staining